Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Clinical trial NCT04211909 · COMPLETED
Trial details
- NCT number
- NCT04211909
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-03
- Primary completion
- 2020-11-12
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.